| Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents M Simeoni, P Magni, C Cammia, G De Nicolao, V Croci, E Pesenti, ... Cancer research 64 (3), 1094-1101, 2004 | 597 | 2004 |
| Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer TJ Abrams, LJ Murray, E Pesenti, V Walker Holway, T Colombo, LB Lee, ... Molecular cancer therapeutics 2 (10), 1011-1021, 2003 | 342 | 2003 |
| Entrectinib, a Pan–TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications E Ardini, M Menichincheri, P Banfi, R Bosotti, C De Ponti, R Pulci, ... Molecular cancer therapeutics 15 (4), 628-639, 2016 | 308 | 2016 |
| PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer P Carpinelli, R Ceruti, ML Giorgini, P Cappella, L Gianellini, V Croci, ... Molecular cancer therapeutics 6 (12), 3158-3168, 2007 | 298 | 2007 |
| Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs … M Menichincheri, E Ardini, P Magnaghi, N Avanzi, P Banfi, R Bossi, ... Journal of medicinal chemistry 59 (7), 3392-3408, 2016 | 273 | 2016 |
| A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity A Montagnoli, B Valsasina, V Croci, M Menichincheri, S Rainoldi, ... Nature chemical biology 4 (6), 357-365, 2008 | 252 | 2008 |
| 1, 4, 5, 6-tetrahydropyrrolo [3, 4-c] pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile D Fancelli, J Moll, M Varasi, R Bravo, R Artico, D Berta, S Bindi, ... Journal of medicinal chemistry 49 (24), 7247-7251, 2006 | 245 | 2006 |
| Polymer-bound paclitaxel derivatives N Mongelli, F Angelucci, E Pesenti, A Suarato, G Biasoli US Patent 5,362,831, 1994 | 241* | 1994 |
| Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations … A Gontarewicz, S Balabanov, G Keller, R Colombo, A Graziano, E Pesenti, ... Blood, The Journal of the American Society of Hematology 111 (8), 4355-4364, 2008 | 224 | 2008 |
| PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity C Soncini, P Carpinelli, L Gianellini, D Fancelli, P Vianello, L Rusconi, ... Clinical Cancer Research 12 (13), 4080-4089, 2006 | 203 | 2006 |
| Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase R Colombo, M Caldarelli, M Mennecozzi, ML Giorgini, F Sola, P Cappella, ... Cancer research 70 (24), 10255-10264, 2010 | 200 | 2010 |
| Polymer-bound camptothecin: initial biodistribution and antitumour activity studies VR Caiolfa, M Zamai, A Fiorino, E Frigerio, C Pellizzoni, R d’Argy, ... Journal of controlled release 65 (1-2), 105-119, 2000 | 192 | 2000 |
| 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding P Pevarello, MG Brasca, R Amici, P Orsini, G Traquandi, L Corti, C Piutti, ... Journal of medicinal chemistry 47 (13), 3367-3380, 2004 | 186 | 2004 |
| Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity E Pesenti, F Sola, N Mongelli, M Grandi, F Spreafico British journal of cancer 66 (2), 367-372, 1992 | 165 | 1992 |
| The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition E Ardini, R Bosotti, AL Borgia, C De Ponti, A Somaschini, R Cammarota, ... Molecular oncology 8 (8), 1495-1507, 2014 | 153 | 2014 |
| 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization P Pevarello, MG Brasca, P Orsini, G Traquandi, A Longo, M Nesi, F Orzi, ... Journal of medicinal chemistry 48 (8), 2944-2956, 2005 | 146 | 2005 |
| NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies B Valsasina, I Beria, C Alli, R Alzani, N Avanzi, D Ballinari, P Cappella, ... Molecular cancer therapeutics 11 (4), 1006-1016, 2012 | 133 | 2012 |
| Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and … G Papeo, H Posteri, D Borghi, AA Busel, F Caprera, E Casale, M Ciomei, ... Journal of medicinal chemistry 58 (17), 6875-6898, 2015 | 130 | 2015 |
| Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease E Radaelli, R Ceruti, V Patton, M Russo, A Degrassi, V Croci, F Caprera, ... Histology and histopathology 24 (7), 879-891, 2009 | 129 | 2009 |
| DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin M Broggini, HM Coley, N Mongelli, E Pesenti, MD Wyatt, JA Hartley, ... Nucleic Acids Research 23 (1), 81-87, 1995 | 127 | 1995 |
